The priming, boosting, and restoration of memory cytotoxic CD8+ T lymphocytes by vaccination or
immunotherapy in vivo is an area of active research. Particularly,
nucleic acid-based compounds have attracted attention due to their ability to elicit strong Ag-specific CTL responses as a
vaccine adjuvant.
Nucleic acid-based compounds have been shown to act as anticancer monotherapeutic agents even without coadministration of
cancer Ag(s); however, so far they have lacked efficacy in clinical trials. We recently developed a second-generation TLR9 agonist, a humanized CpG
DNA (K3) complexed with
schizophyllan (SPG),
K3-SPG, a nonagonistic
Dectin-1 ligand.
K3-SPG was previously shown to act as a potent monoimmunotherapeutic agent against established
tumors in mice in vivo. In this study we extend the monoimmunotherapeutic potential of
K3-SPG to a nonhuman primate model.
K3-SPG activated monkey plasmacytoid dendritic cells to produce both IFN-α and
IL-12/23 p40 in vitro and in vivo. A single injection s.c. or i.v. with
K3-SPG significantly increased the frequencies of activated memory CD8+ T cells in circulation, including Ag-specific memory CTLs, in cynomolgus macaques. This increase did not occur in macaques injected with free CpG K3 or
polyinosinic-polycytidylic acid. Injection of 2 mg
K3-SPG induced mild systemic
inflammation, however, levels of proinflammatory serum
cytokines and circulating neutrophil influx were lower than those induced by the same dose of
polyinosinic-polycytidylic acid. Therefore, even in the absence of specific Ags, we show that
K3-SPG has potent Ag-specific memory CTL response-boosting capabilities, highlighting its potential as a monoimmunotherapeutic agent for chronic
infectious diseases and
cancer.